Kolexia
Ojeda Uribe Mario Hématologie
Ojeda Uribe Mario
Hématologie
Hôpital Emile Muller
Mulhouse, France
131 Activités
369 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Purpura thrombotique thrombocytopénique Purpura Purpura thrombopénique Lymphomes Microangiopathies thrombotiques Myélofibrose primitive

Collaborateurs

Voir plus
Eisenmann Jean-Claude
Eisenmann Jean-Claude
Hôpital Hasenrain, Mulhouse, France
Drenou Bernard
Drenou Bernard
Hôpital Emile Muller, Mulhouse, France
Hunault-Berger Mathilde
Hunault-Berger Mathilde
Hôpital Larrey Angers, Angers, France
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France

Industries

Voir plus
Novartis
18 collaboration(s)
Dernière en 2023
A+A
8 collaboration(s)
Dernière en 2022
Pfizer
6 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Blood advances   29 août 2023
Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Journal of neurology   01 juillet 2023
A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome: A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Essai Clinique (Groupe Français des Myélodysplasies)   02 janvier 2023
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome: A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Essai Clinique (Groupe Français des Myélodysplasies)   02 janvier 2023
Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
Annual Meeting Abstracts 2022   15 novembre 2022
Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
Annual Meeting Abstracts 2022   15 novembre 2022